The classic website will no longer be available as of June 25, 2024. Please use the modernized ClinicalTrials.gov.
Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Study of Obeldesivir in Nonhospitalized Participants With COVID-19 (OAKTREE)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT05715528
Recruitment Status : Completed
First Posted : February 8, 2023
Last Update Posted : February 7, 2024
Sponsor:
Information provided by (Responsible Party):
Gilead Sciences

Brief Summary:
The goal of this clinical study is to test if obeldesivir (formerly GS-5245) is safe and effective for the treatment of coronavirus disease 2019 (COVID-19) in participants who have a standard risk of developing severe illness. This study will also measure how much obeldesivir gets into the blood and how long it takes for the body to get rid of it.

Condition or disease Intervention/treatment Phase
COVID-19 Drug: Obeldesivir Drug: Obeldesivir Placebo Phase 3

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 2011 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Triple (Participant, Care Provider, Investigator)
Masking Description: Participants, personnel directly involved in the conduct of study, and sponsor will not know the treatment participants received.
Primary Purpose: Treatment
Official Title: A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of GS-5245 for the Treatment of COVID-19 in Nonhospitalized Participants
Actual Study Start Date : February 8, 2023
Actual Primary Completion Date : November 29, 2023
Actual Study Completion Date : January 23, 2024

Resource links provided by the National Library of Medicine


Arm Intervention/treatment
Experimental: Obeldesivir
Participants will receive obeldesivir 350 mg twice daily for 5 days.
Drug: Obeldesivir
Tablet administered orally without regard to food.
Other Name: GS-5245

Placebo Comparator: Obeldesivir Placebo
Participants will receive obeldesivir placebo twice daily for 5 days.
Drug: Obeldesivir Placebo
Tablet administered orally without regard to food.




Primary Outcome Measures :
  1. Time to Coronavirus Disease 2019 (COVID-19) Symptom Alleviation by Day 29 [ Time Frame: First dose date up to Day 29 ]
  2. Percentage of Participants Experiencing Treatment-emergent Adverse Events (TEAEs) [ Time Frame: First dose date up to Day 5 plus 30 days ]
  3. Percentage of Participants Experiencing Laboratory Abnormalities [ Time Frame: First dose date up to Day 5 plus 30 days ]
  4. Percentage of Participants Experiencing Serious Adverse Events (SAEs) and Adverse Events (AEs) Leading to Study Drug Discontinuation [ Time Frame: First dose date up to Day 5 plus 30 days ]

Secondary Outcome Measures :
  1. Time to COVID-19 Symptom Resolution by Day 29 [ Time Frame: Day 1 up to 29 ]
  2. Proportion of Participants with COVID-19 related Medically Attended Visits (MAVs) or All-cause Death by Day 29 [ Time Frame: Up to Day 29 ]
  3. Proportion of Participants with Moderate Relapse of COVID-19 Symptoms by Day 29 [ Time Frame: Up to Day 29 ]
  4. Proportion of Participants with COVID-19 related Hospitalization or All-cause Death by Day 29 [ Time Frame: Up to Day 29 ]
  5. Change from Baseline in Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Nasal Swab Viral Load at Day 5 [ Time Frame: Baseline, Day 5 ]
  6. Time to Antigen Negativity [ Time Frame: Day 1 up to Day 29 ]
  7. Proportion of Participants with Viral Antigen Rebound [ Time Frame: First dose date up to Day 29 ]
  8. Plasma Concentrations of GS-441524 (Metabolite of Obeldesivir) [ Time Frame: Day 1, Day 3, and Day 5 ]
  9. Pharmacokinetic (PK) Parameter: AUCtau of GS-441524 [ Time Frame: Day 1, Day 3, and Day 5 ]
    AUCtau is defined as the area under the concentration versus time curve over the dosing interval

  10. PK Parameter: Ctau of GS-441524 [ Time Frame: Day 1, Day 3, and Day 5 ]
    Ctau is defined as the observed drug concentration at the end of the dosing interval

  11. PK Parameter: Cmax of GS-441524 [ Time Frame: Day 1, Day 3, and Day 5 ]
    Cmax is defined as the maximum observed plasma concentration of drug

  12. Proportion of Participants with Relapse of COVID-19 Symptoms by Day 29 [ Time Frame: Up to Day 29 ]


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   12 Years to 64 Years   (Child, Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Key Inclusion Criteria:

  • Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection confirmed, ≤ 3 days before randomization, by polymerase chain reaction (PCR), rapid antigen test, or an approved alternative assay. Serologic tests will not be accepted.
  • Willing and able to complete the coronavirus disease 19 (COVID-19) symptom questionnaire prior to first dose and daily throughout the study period.
  • Initial onset of COVID-19 signs/symptoms ≤ 3 days before randomization with ≥ 2 of the following targeted symptoms, at moderate or higher severity, present at randomization.

    • Stuffy or runny nose.
    • Sore throat.
    • Shortness of breath (difficulty breathing).
    • Cough.
    • Low energy or tiredness.
    • Muscle or body aches.
    • Headache.
    • Chills or shivering.
    • Feeling hot or feverish.
  • Not currently hospitalized or requiring hospitalization.

Key Exclusion Criteria:

  • Any risk factors for progression to severe disease.
  • Planning to receive a direct acting antiviral or monoclonal antibody against SARS-CoV-2 for the treatment of COVID-19.
  • Received any direct acting antiviral drug or monoclonal antibody against SARS-CoV-2 for the treatment of COVID-19 < 28 days or < 5 half-lives, whichever is longer, before randomization.
  • Received any convalescent COVID-19 plasma or other antibody-based anti-SARS-CoV-2 prophylaxis at any time prior to study entry.
  • Received an COVID-19 vaccine (including booster dose) < 120 days before randomization.
  • Self-reported COVID-19 diagnosis < 120 days before randomization.
  • Anticipated need for hospitalization < 48 hours after randomization.
  • New oxygen requirement < 24 hours before randomization.
  • Known influenza, or any other suspected or confirmed concurrent active systemic infection other than COVID-19 that may interfere with the evaluation of response to the study drug.
  • Known history of chronic liver disease, limited to cirrhosis, nonalcoholic steatohepatitis, alcoholic liver disease, and autoimmune hepatitis.
  • Undergoing dialysis, or known history of chronic kidney disease.
  • Persistent symptoms from previous COVID-19 illness that may interfere with the evaluation of response to the study drug.
  • Pregnant or breastfeeding.
  • Unwilling to use protocol-mandated contraception.
  • Any other factor, including inability to complete the patient-reported outcome (PRO) questionnaire for the primary endpoint, making the individual, in the opinion of the investigator, unsuitable to participate in the study.
  • Concurrent participation/enrollment in a separate therapeutic clinical study.

Note: Other protocol defined Inclusion/Exclusion criteria may apply.


Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT05715528


Locations
Show Show 113 study locations
Sponsors and Collaborators
Gilead Sciences
Investigators
Layout table for investigator information
Study Director: Gilead Study Director Gilead Sciences
Additional Information:
Layout table for additonal information
Responsible Party: Gilead Sciences
ClinicalTrials.gov Identifier: NCT05715528    
Other Study ID Numbers: GS-US-611-6549
jRCT2031230285 ( Other Identifier: Japan Registry of Clinical Trials )
First Posted: February 8, 2023    Key Record Dates
Last Update Posted: February 7, 2024
Last Verified: February 2024
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
Additional relevant MeSH terms:
Layout table for MeSH terms
COVID-19
Pneumonia, Viral
Pneumonia
Respiratory Tract Infections
Infections
Virus Diseases
Coronavirus Infections
Coronaviridae Infections
Nidovirales Infections
RNA Virus Infections
Lung Diseases
Respiratory Tract Diseases